ICAD is not out of the woods yet. We need to see a genuine revenue/earnings pop along with market acceptance of new products. It is heartening to see the PPS showing such strength in a flimsy macro market.
Hey foogie88, it was a good CC. Good to hear management's optimism for growth in skin EBx given the satisfactory reimbursement levels being witnessed. Good to hear of apparent strong interest in the tomo diagnostic and breast density products. Good to hear about the strong growth foreseen in H2 as sales efforts mature and further into 2017 as next generation diagnostic and therapy tools fill the pipeline. The optimism was refreshing after so many quarters of "hope and wait". At least now we have some substance behind the patience being demanded..
The quarterly financial results were disappointing but not altogether unexpected. Not crippling by any means. Management's inability to provide revenue/earnings guidance will persist in keeping many investors away from major investments in ICAD for the next few quarters. I heard enough to maintain my position and expect strong PPS performance as ICAD's revenue/EPS growth unfolds. Patience will be rewarded. What did you think?
Your opinion is foolish and biased, IMO. From the CC transcript:
"We generated $64 million in cash from operations in the quarter, up 31% from $49 million in Q1 last year. Inventories were $81 million at the end of the quarter as expected. With the strong cash generation and value of our shares, we invested $12 million in capital projects, and repurchased $50 million of our common stock during the quarter.
While we ended the quarter with nearly $30 million in cash and securities, we continue to expect to operate with less cash on hand during the year. This will likely include temporary draws from our $150 million revolver during seasonally low cash periods like the second quarter."
No cash? Secondary offering? PLEEEAAASE!
The earnings CC was informative. Management made a sharp and knowledgeable presentation. They know their business, as they should. Reiterated the goal of $2.75 EPS for 2019, a near tripling of the impaired $.97 reported for 2015. Significant share repurchases will help this goal along. Make your own assumptions for a PE on future EPS. I see solid PPS growth ahead.
SCSS beats $.20 consensus, earning $.27 in the latest quarter. Reiterates full year EPS guidance of $1.25-1.45, up from $.97 in 2015. The 15 PE on guidance is a bargain given earnings growth.
Thank you, lincoln1909vdb. I googled the episode and the previous night's segment dealing with retail shopping applications of VR/AR. Paraphrasing haschultz1, those who don't "get" the enormous potential of VR/AR lack imagination. Whether its gaming, engineering/manufacturing applications, retail showroom uses, etc., Himax will supply a huge amount of hardware to fill demand in the years ahead.
Last year's Q4 report was issued June 29, 2015. They used nearly all of the 90 days allowed by the SEC for a year-end report. No other official word out.
Hey rknecht17, my view hasn't changed a bit for the simple reason no news has come out since the CC. I still expect the SP to move based on revenue growth, EPS, margin trends and backlog growth - in no particular order. I'm long, reflecting my near/intermediate term optimism. That optimism is rooted in recent margin improvement and the backlog growth reported over the past 2 quarters. Other takers?
For you TA enthusiasts, note that ICAD's 200 day SMA bottomed out on March 10 at $3.92 and has slowly begun to climb. A Golden Cross of the 50 SMA upward through the 200 happened in early February but the 200 was still declining. A school of TA thought looks for both lines to be moving upward for full affect. We have that now, for what it's worth.
Thank you for the informed response, Luke. I'm looking forward to upcoming management conference calls at which recent EBx reimbursement developments may be discussed.
Good luck with your trade, traderrob88. What you envision for the SP may happen. Nearly anything is possible in the short term. In fact, I may thin my long position (dating to 2003) if it hits $51-52 soon.
I don't mean to argue with your opinion. I only meant to correct your "facts". Best regards.
traderrob88, did you listen to the earnings call or read the transcript as I did? You said “DSP in their earnings call said they were getting shredded by online vendors”. Your statement is a falsehood. If I’m wrong, prove it. NO WHERE was any such thing mentioned or inferred. This makes your other statements sound like a bitter, biased rant against DKS rather than an honest opinion.
You went on the say DKS management…”used the same excuse as apparel did with "unseasonably warm weather" They sell sporting goods!!!! Warm weather should have benefitted them.. but what do I know...”. Well, you apparently need to know more! If you had listened to the earnings call, you would have heard Ed Stack say “The results for the quarter were significantly impacted negatively by performance of cold weather-related categories. These categories include jackets, fleece, cold weather compression, boots and accessories. They represent a significant portion of our business in the fourth quarter and they were down double digits.”
He went on to say “Looking outside the cold weather categories, the balance of our business performed very well, comping up nearly 3%. In particular, we continue to be very pleased with our performance across important growth categories such as Athletic Footwear, Licensed, and our Women's business where we have invested in improved product content, merchandise presentation, shopping experience and marketing.”
Don’t you get it, traderrob88? DKS is a national retailer with significant sales volume in cold weather areas unlike Atlanta. Above average temps in winter lead to decreased sales of winter goods in cold weather climes. That is only common sense.
Speaking of online vendors, the DKS eCommerce business increased approximately 19% for the full year to over $748 million. They are doing well in that regard.
Hey traderrob88, following the competition is a good practice. I monitored TSA's performance back when it was a public company and was unimpressed with their published financials. Of course, DKS outperformed TSA at every turn and prospered.
How do you assess Academy's performance given their non-public ownership (i.e., no public disclosure of financials)? You have heard through unsubstantiated talk that they are DKS's biggest threat. That means nothing to me if you can't quantify the risk. Innuendo is not something I want to base my investment decisions on.
Has Jay moved to UBS?
From Seeking Alpha:
Himax slides after UBS reiterates Sell, questions VR/AR enthusiasm
Mar 18 2016, 13:51 ET | About: Himax Technologies, Inc. (HIMX) | By: Eric Jhonsa, SA News Editor [Contact this editor with comments or a news tip]
UBS has reiterated a Sell rating and $4.40 target on Himax (HIMX -3.3%), while declaring shares are pricing in too much optimism. In particular, the firm thinks there's still a high degree of uncertainty regarding Himax's VR/AR product sales, in spite of the market's excitement.
The note comes a day after Himax closed just $0.08 below a 52-week high of $10.99 (set on Monday). It also comes two months after Himax stated it has landed design wins related to display panels used in VR devices from "two brand-leading VR companies" - Morgan Stanley has reported of OLED driver IC design wins for the Oculus Rift and HTC's Vive headset.
Himax has also unveiled a wafer level optics (WLO) solution that enables 3D depth sensing/scanning for VR/AR devices and smartphones (among other products). In the near-term, VR/AR headset volumes are expected to be a fraction of those seen for popular smartphones.
A very large Pennsylvania health insurer, Highmark, announced Thursday that they are introducing a new way to pay for treating people with cancer. News reports say it "attacks the deeply entrenched practice of paying doctors for the number of procedures they perform". The new arrangement will supposedly provide a bundled payment for an episode of care on the condition doctors "follow treatment guidelines that have been proven effective". I also understand another huge PA medical insurance provider, UPMC, is considering a similar approach.
I'm aware doctors have been having problems being fairly reimbursed for skin cancer treatments using ICAD's technology. Breast cancer doctors also have been slow to adopt ICAD's breast cancer technology because it necessitates FEWER treatments, reducing their revenue. Any professionals out there familiar with whether the above insurance changes might help ICAD prosper? If so, in what ways? It sounds promising on the surface.
Hey coldpizza22, you must be either short or bitter telling from your mention of something that happened in August 2012. Which is it?
commandor, do you give any credence to the theory of general market weakness during presidential election years? This would lead one to believe a bull run will be deferred until later 2016. Do you expect the bullishness to begin sooner or later?